BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//AssetMemo//Readout calendar//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Balcinrenone readouts · AssetMemo
X-WR-CALDESC:Upcoming readouts of Balcinrenone\, from ClinicalTrials.gov es
 timates.
REFRESH-INTERVAL;VALUE=DURATION:PT12H
X-PUBLISHED-TTL:PT12H
BEGIN:VEVENT
UID:NCT06307652-594@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20270416
DTEND;VALUE=DATE:20270417
SUMMARY:Balcinrenone: Phase 3 readout est. (NCT06307652)
DESCRIPTION:Balcinrenone\, phase 3\, Heart Failure.\nStudy: Study to Evalua
 te the Effect of Balcinrenone/Dapagliflozin in Patients With Heart Failure
  and Impaired Kidney Function\nEstimated primary completion: 16 April 2027
 . This is a ClinicalTrials.gov estimate\, not a confirmed readout date\, a
 nd it can move.\nDrug page: https://assetmemo.bio/drug/balcinrenone#upcomi
 ng-events\nRegistry record: https://clinicaltrials.gov/study/NCT06307652
URL:https://assetmemo.bio/drug/balcinrenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
BEGIN:VEVENT
UID:NCT07624305-594@assetmemo.bio
DTSTAMP:20261121T004043Z
DTSTART;VALUE=DATE:20300701
DTEND;VALUE=DATE:20300702
SUMMARY:Balcinrenone: Phase 3 readout est. (NCT07624305)
DESCRIPTION:Balcinrenone\, phase 3\, Chronic Kidney Disease.\nStudy: A Phas
 e III Study to Evaluate the Effect of Balcinrenone/Dapagliflozin in Patien
 ts With CKD Stage 3b and 4 (BalanceD-CKD)\nEstimated primary completion: 1
  July 2030. This is a ClinicalTrials.gov estimate\, not a confirmed readou
 t date\, and it can move.\nDrug page: https://assetmemo.bio/drug/balcinren
 one#upcoming-events\nRegistry record: https://clinicaltrials.gov/study/NCT
 07624305
URL:https://assetmemo.bio/drug/balcinrenone#upcoming-events
TRANSP:TRANSPARENT
END:VEVENT
END:VCALENDAR
